TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04319237

Intervention type: BEHAVIORAL
Intervention: Comprehensive Score for Financial Toxicity (COST) measure
Description: The COST is a questionnaire made up of 11 statements around topics including costs, concerns and resources and is designed to measure financial toxicity. The user answers questions about their concern over finances numbered from 0-4, with 0 being not at all and 4 being very much.
Study: NCT03913416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed model
Description: Before surgery, the surgeon will have a 3D printed model of the pulmonary malformation as well as the lung, the rib cage and the tracheal trunk based on the initial scanner images. He will then be able to train and plan the surgical strategy, as well as to discuss the pulmonary exclusion with the anesthetist.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group is composed of patients operated with standard surgery
Study: NCT00667030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and aerobic exercise training
Description: Weight loss and aerobic exercise training
Study: NCT03758417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-B38M CAR-T Cell
Description: Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
Study: NCT00504309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corn Oil Placebo, 4 capsules/day for 8 weeks
Description: 4 capsules per day of corn oil placebo for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corn Oil Placebo, 4 capsules/day for 8 weeks
Description: 4 capsules per day of corn oil placebo for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corn Oil Placebo, 4 capsules/day for 8 weeks
Description: 4 capsules per day of corn oil placebo for 8 weeks
Study: NCT03306381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Elimination of certain products.
Study: NCT03888274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearUP Sinus Pain Relief
Description: Microcurrent Device Treatment
Study: NCT00649948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 500 mg
Description: 500mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage XR 500 mg
Description: 500mg, single dose fed
Study: NCT02517229

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight

Intervention type: OTHER
Group type: OTHER
Intervention: balance control measurements

Intervention type: DEVICE
Group type: OTHER
Intervention: electromagnetic maneuverable postural platform
Study: NCT01292538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia GLS
Description: 532 nm green diode low level laser light device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo laser
Description: Sham light output with no therapeutic benefit
Study: NCT05150288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMO-supplemented infant formula
Description: Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMO-supplemented infant formula
Description: Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
Study: NCT00508846

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Two-part telephone questionnaire lasting about 60 minutes total.
Study: NCT01849809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Ventral Capsulotomy
Study: NCT00724503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres yttrium-90 microspheres
Description: SIR-Spheres microspheres (yttrium-90 \[Y-90\] labelled resin microspheres), hepatic artery injection administered on Day 3 or 4 of cycle 1.~mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic chemotherapy (FOLFOX)
Description: mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2.
Study: NCT04979013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Abstinence
Description: Smokers will be switched to smoking abstinence for 14 days
Study: NCT02608606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: compared oral administration versus sublingual administration of tacrolimus.
Study: NCT02777788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JinFuKang
Description: treated with chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XingZaoRuanJian
Description: treated with chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin
Study: NCT01893008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.~Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.~Training will be started after the chemoradiation period (if applicable).
Study: NCT03401333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging and Brief Negotiation Interview
Description: An in-person brief motivational intervention coupled with 4 weeks of motivational text messages
Study: NCT04645108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching
Description: The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Noom Healthy Weight; mobile behavior change program for weight loss
Description: The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity. During the first week of the study, participants will be introduced to the program, and the Noom app.
Study: NCT01990781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD: Lidocaine and dexamethasone
Description: LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L:Lidocaine
Description: Intravenous lidocaine 1.5 mg/kg before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D: Dexamethasone
Description: D:intravenous dexamethasone 8 mg before induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N: Normal saline (placebo)
Description: Normal saline: 2ml
Study: NCT00985374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5mg or 10mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: 16mg/kg iv every 3 weeks
Study: NCT02803541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 day mainstream summer camp experience
Description: see arm description
Study: NCT02937922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AEROBIC
Description: The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: \[(HR max - HR rest) x desired intensity\] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RESISTANCE
Description: The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60 % of a maximum repetition (1-RM) (moderate intensity) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COMBINED
Description: The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise, resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
Study: NCT01301092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: administered intravenous, subcutaneous or intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: administered intravenous, subcutaneous or intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: administered intravenous, subcutaneous or intramuscular
Study: NCT04264585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behaviour therapy
Description: All clients will receive the same materials, namely the UniWellbeing Course, which was developed at Macquarie University, Australia. The UniWellbeing Course is a transdiagnostic intervention targeting symptoms of depression and anxiety, that has been tailored for use in post-secondary students. It comprises 4 online lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model; thought monitoring and challenging; de-arousal strategies and pleasant activity scheduling; graduated exposure; and relapse prevention. Seven supplementary lessons can also be accessed at any time (e.g., sleep, communication). Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) with 4 lesson summaries and homework assignments that facilitate skill acquisition. Therapists will spend \~15 mins. per week/per client.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behaviour therapy
Description: All clients will receive the same materials, namely the UniWellbeing Course, which was developed at Macquarie University, Australia. The UniWellbeing Course is a transdiagnostic intervention targeting symptoms of depression and anxiety, that has been tailored for use in post-secondary students. It comprises 4 online lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model; thought monitoring and challenging; de-arousal strategies and pleasant activity scheduling; graduated exposure; and relapse prevention. Seven supplementary lessons can also be accessed at any time (e.g., sleep, communication). Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) with 4 lesson summaries and homework assignments that facilitate skill acquisition. Therapists will spend \~15 mins. per week/per client.
Study: NCT02140580

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surfactant therapy
Description: Active Comparator
Study: NCT02140580

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Continuation on CPAP
Description: Sham Comparator
Study: NCT00840216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER 500 mg tablets
Description: 1 x 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIAXIN® XL 500 mg tablets
Description: 1 x 500 mg
Study: NCT04264585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Session
Description: Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course. The booster session will include information about maintaining motivation, a review of the ICBT course content and skills, and information about structured problem solving. Clients will also have access to a Do-It-Yourself guide that summarizes the information in the booster session and includes worksheets for clients to practice the problem-solving skills described in the booster.~This booster session will be self-guided (ie. no therapist support is offered).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Session
Description: Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course. The booster session will include information about maintaining motivation, a review of the ICBT course content and skills, and information about structured problem solving. Clients will also have access to a Do-It-Yourself guide that summarizes the information in the booster session and includes worksheets for clients to practice the problem-solving skills described in the booster.~This booster session will be self-guided (ie. no therapist support is offered).
Study: NCT03110835

Intervention type: RADIATION
Intervention: Radioiodine
Description: Administration of radioiodine

Intervention type: RADIATION
Intervention: Radioiodine
Description: Administration of radioiodine
Study: NCT00286455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
Study: NCT03827642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.
Study: NCT00840073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg Tablets
Description: 1 x 4 mg, single-dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavik® 4 mg Tablets
Description: 1 x 4 mg, single-dose fed
Study: NCT00218257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 200mg progesterone twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01370369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 99903)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 99903)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 99903)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 99903)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 99903)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 99903)
Study: NCT04234334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consume 2 eggs with spinach per day
Description: Participants will be randomly allocated to consume either 2 eggs or 2 egg substitutes with spinach daily for 4 weeks and after a 3-week wash out, they will be allocated to the alternate treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Subsitute with spinach per day
Description: Egg Subsitute with spinach per day
Study: NCT03323008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prototype
Description: Usability testing and System Usability Scale
Study: NCT01838941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Description: Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:~* 6 g/day in children \< 30 kg, in 3 divided doses (2 g at meal time)~* 12 g/day in children \> 30 kg, in 4 divided doses (3 g at meal time and bed time).
Study: NCT00144014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V10153
Description: Single acute intravenous bolus dose up to 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V10153
Description: Single acute intravenous bolus dose up to 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V10153
Description: Single acute intravenous bolus dose up to 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V10153
Description: Single acute intravenous bolus dose up to 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V10153
Description: Single acute intravenous bolus dose up to 10 mg/kg
Study: NCT02321098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loceryl NL + Cosmetic varnish
Description: Loceryl NL + Cosmetic varnish once/week for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loceryl NL 12 weeks
Description: Loceryl NL once/week for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loceryl NL 15 months
Description: Loceryl once/week for additional 15 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loceryl NL 15 months
Description: Loceryl once/week for additional 15 months
Study: NCT03084250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2A
Description: 180μg/week, 48 weeks; 135μg/week,48weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir, entecavir,tenofovir, either of them
Description: Adefovir, entecavir,tenofovir, either of them is ok
Study: NCT01124305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Patient Instrumentation
Description: Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Instrumentation
Description: Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
Study: NCT02979522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine infusion